SNIP 2026 puts neuro-HIV and substance use research at the center of brain health science
The 30th Annual Society on Neuroimmune Pharmacology conference will gather investigators in Annapolis, Maryland, from May 3 to 6, 2026, with a program built around neuro-HIV, substance use disorders, and related neurodegenerative conditions. The meeting is organized to bridge preclinical science, translational work, and clinical research, a combination that mirrors the complexity of brain injury in people living with HIV and those exposed to drugs of abuse. Across four days, the agenda emphasizes how immune signaling, viral persistence, and neurotoxicity intersect in the central nervous system.
The scope is broad, but the scientific theme is cohesive. HIV infection of the brain, chronic neuroinflammation, and drug-related injury rarely occur in isolation; they often overlap with aging and with additional neurologic disease processes. That overlap is what gives the conference its clinical weight. Researchers will spend the meeting examining how neuronal injury develops, how inflammatory pathways are sustained, and how stimulants, opioids, and cannabis may either worsen or modify the biology of neuropathogenesis.
The first day opens with two concurrent preconference symposia. One focuses on Single Cell HIV and SUD Effects on the Brain: SCORCH Consortium Progress, with an overview and seven investigator presentations centered on the Single Cell Opioid Response in the Context of HIV consortium. The second symposium, Catalyzing Interdisciplinary Research on HIV-Associated Co-occurring Conditions, points to a growing recognition that HIV-associated brain disease does not sit neatly in one specialty silo. Immunology, addiction science, neurology, and aging research all converge on the same tissue: the vulnerable brain.
The opening evening poster session is set to feature 52 abstracts from early-stage-career investigators, including presenters supported by travel awards. That detail matters because the field depends on young scientists who can move quickly between bench, animal, and human studies. A conference built around early-career participation tends to generate more cross-disciplinary exchange, and neuroimmune pharmacology is a field where those exchanges can shape future trial design, biomarker selection, and mechanistic hypotheses.
A program built around brain injury, viral persistence, and addiction biology
The middle of the meeting expands into 11 symposia, two memorial lectures, and a plenary presentation, with 62 speakers overall, including 12 early-stage-career investigator travel awardees. Across those sessions, the scientific questions are likely to run from cellular response to clinical expression: how does HIV alter brain cells, how do substances of abuse reshape that response, and what happens when aging and neurodegeneration are added to the picture? The meeting’s structure reflects a field that has moved beyond single-cause thinking. In real patients, brain injury often reflects layered exposure, not one isolated insult.
The conference will feature 185 abstracts in total, covering 70 oral presentations and 115 posters. Those numbers suggest a substantial research volume, but the more important point is the range of inquiry. Mechanistic studies can clarify why certain viral or inflammatory signals persist in the brain for years, while observational studies can identify clinical patterns in cognition, neurologic decline, or comorbid disease burden. In practice, both are necessary. Without mechanistic insight, findings remain descriptive; without clinical observation, bench science can drift away from bedside relevance.
Neuroinflammation is a recurring thread running through the program. HIV brain infection can trigger immune activation and neuronal stress, and that vulnerability may be amplified by drugs of abuse, especially stimulants and opioids. Cannabis also appears in the discussion, not as a single-direction variable, but as another exposure that may alter neuropathology in ways still being sorted out by the field. The biological logic is straightforward even when the clinical presentation is not: inflammatory activation, disrupted neuronal homeostasis, and cellular stress responses can accumulate over time and shape long-term neurologic outcomes.
Aging adds another layer of urgency. People living with HIV are older on average than in previous eras of the epidemic, and many also have substance use disorders. When aging collides with chronic viral exposure and substance-related injury, the brain faces multiple pressures at once. That is one reason the conference explicitly includes recent work on how aging and neurodegenerative disorders may influence brain health in this population. The meeting is not treating these conditions as separate tracks; it is treating them as intersecting risks.
Nora Volkow and Avindra Nath frame the meeting’s scientific priorities
The plenary lecture will be delivered by Dr. Nora Volkow, who will address the priorities of HIV research at the National Institute on Drug Abuse. Her involvement situates the conference within a broader federal research agenda that links addiction science to neuroHIV. In a field where funding priorities can shape the direction of mechanistic and clinical work, that perspective carries practical importance for investigators planning studies on biomarkers, neuropathology, and treatment response.
The banquet speaker, Dr. Avindra Nath, will focus on how viruses, particularly retroviruses, may invade the brain, infect brain cells, and adapt to the local environment for decades. He will also address the possibility that viral persistence and mutation may contribute to neurodegenerative disorders. That topic reaches to the core of the meeting’s scientific identity. Viral persistence in the nervous system is not merely a virology question; it is a neurobiology question, a pathology question, and a clinical question because the consequences can emerge years after the initial infection.
One sentence captures the urgency of the conference’s theme: the brain can remain biologically active long after the original infectious or toxic insult has passed.
Another is equally direct: persistent neuroinflammation can become the mechanism through which remote exposures translate into chronic cognitive and neurologic injury.
SNIP has also maintained a clear emphasis on career development, and that remains visible in the number of poster opportunities and travel awards reserved for early-stage investigators. In a research area as technically demanding as neuroimmune pharmacology, the future depends on scientists who can integrate cellular biology, clinical phenotyping, and translational methods without losing sight of the patient. The Annapolis meeting is designed to support exactly that kind of work.
What this conference does not do is claim final answers. It does, however, assemble the questions most likely to matter next: how HIV-related brain injury evolves over time, how substances of abuse alter that trajectory, how aging changes the equation, and where the boundary lies between reversible dysfunction and progressive neurodegeneration. Those are the questions now shaping neuro-HIV research, and they will define the discussions in Annapolis across the four-day program.